| 1. |
Delling FN, Vasan R. Epidemiology and pathophysiology of mitral valve prolapse: new insights into disease progression, genetics, and molecular basis. Circulation, 2014, 129(21): 2158-2170.
|
| 2. |
Delgado V, Ajmone Marsan N, Bonow R, et al. Degenerative mitral regurgitation. Nat Rev Dis Primers, 2023, 9(1): 70.
|
| 3. |
Coffey S, Roberts-Thomson R, Brown A, et al. Global epidemiology of valvular heart disease. Nat Rev Cardiol, 2021, 18(12): 853-864.
|
| 4. |
Aluru J, Barsouk A, Saginala K, et al. Valvular heart disease epidemiology. Med Sci (Basel), 2022, 10(2): 32.
|
| 5. |
Otto C, Nishimura R, Bonow R, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 143(5): e35-e71.
|
| 6. |
Wang C, Song M, Chen H, et al. Global epidemiologic trends and projections to 2030 in non-rheumatic degenerative mitral valve disease from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019. Rev Cardiovasc Med, 2024, 25(7): 269.
|
| 7. |
付宏利, 閆昱名, 關禮春, 等. 1993—2023 年中國與全球老年非風濕性鈣化性主動脈瓣疾病負擔的年齡-時期-隊列分析及未來趨勢預測. 中國心血管病研究, 2025, 23(12): 1141-1149.Fu HL, Yan YM, Guan LC, et al. Age-period-cohort analysis and future trend projections of the burden of non-rheumatic calcific aortic valve disease in older adults in China and worldwide, 1993-2023. Chin J Cardiovasc Res, 2025, 23(12): 1141-1149.
|
| 8. |
尹光嬌, 祖木熱提古麗·牙克甫, 王紫薇, 等. 1990—2019 年中國與全球風濕性心臟病疾病負擔分析. 武漢大學學報 (醫學版), 2023, 44(7): 841-847.Yin GJ, Zumratgul Y, Wang ZW, et al. Disease burden analysis on rheumatic heart disease in China and the world from 1990 to 2019. Med J Wuhan Univ, 2023, 44(7): 841-847.
|
| 9. |
GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet, 2025, 406(10513): 1873-1922.
|
| 10. |
Kim H, Fay M, Feuer E, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med, 2000, 19(3): 335-351.
|
| 11. |
Gammie J, Chikwe J, Badhwar V, et al. Isolated mitral valve surgery: the Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis. Ann Thorac Surg, 2018, 106(3): 716-727.
|
| 12. |
Romano M, McCarthy P, Baldridge A, et al. Should mitral valve replacement age guidelines be lowered due to better bioprosthetic mitral valve durability? J Thorac Cardiovasc Surg, 2024, 168(5): 1448-1458.
|
| 13. |
Stone G, Lindenfeld J, Abraham W, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med, 2018, 379(24): 2307-2318.
|
| 14. |
Almuzainy S, Lemine M, Aljubeh R, et al. Comparative efficacy and safety of transcatheter mitral valve repair versus mitral-valve surgery in elderly patients with mitral regurgitation: a systematic review and meta-analysis. J Saudi Heart Assoc, 2024, 36(4): 316-334.
|
| 15. |
McDonagh T, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 2023, 44(37): 3627-3639.
|
| 16. |
Kreutz R, Brunstr?m M, Burnier M, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med, 2024, 126: 1-15.126-121.
|
| 17. |
d'Arcy J, Coffey S, Loudon M, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J, 2016, 37(47): 3515-3522.
|
| 18. |
Maciorowska M, Zhang L, Tokhi B, et al. Transthoracic and transesophageal echocardiography in the diagnosis and management of mitral regurgitation. Curr Cardiol Rep, 2025, 27(1): 165.
|
| 19. |
Small A, Yutzey K, Binstadt B, et al. Unraveling the mechanisms of valvular heart disease to identify medical therapy targets. Circulation, 2024, 150(6): e109-e128.
|
| 20. |
Yang J, Bai R, Wang L, et al. A projection of life expectancy based on the Global Burden of Disease Study 2019: China, 1990-2030. China CDC Wkly, 2023, 5(2): 40-44.
|
| 21. |
Center for Cardiovascular Diseases the Writing Committee of the Report on Cardiovascular Health and Diseases in China, Hu SS. Report on cardiovascular health and diseases in China 2023: an updated summary. Biomed Environ Sci, 2024, 37(9): 949-992.
|
| 22. |
Remenyi B, ElGuindy A, Smith S, et al. Valvular aspects of rheumatic heart disease. Lancet, 2016, 387(10025): 1335-1346.
|
| 23. |
Zühlke L, Engel M, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J, 2015, 36(18): 1115-1122.
|
| 24. |
Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India: current epidemiology and future directions. Circulation, 2016, 133(16): 1605-1620.
|
| 25. |
DesJardin J, Chikwe J, Hahn R, et al. Sex differences and similarities in valvular heart disease. Circ Res, 2022, 130(4): 455-473.
|
| 26. |
Woodward H, Zhu D, Hadoke P, et al. Regulatory role of sex hormones in cardiovascular calcification. Int J Mol Sci, 2021, 22(9): 4620.
|
| 27. |
Delwarde C, Capoulade R, Mérot J, et al. Genetics and pathophysiology of mitral valve prolapse. Front Cardiovasc Med, 2023, 10: 1077788.
|
| 28. |
Consoli L, Majeed M, Cetinel E, et al. Sex-based differences in outcomes of mitral valve surgery: a meta-analysis of propensity score-matched studies with reconstructed time-to-event data. Am Heart J Plus, 2026, 61: 100682.
|
| 29. |
Fan J, Chen J, Wang L, et al. The global burden and attributable risk factor analysis of cardiovascular disease between females and males, 1990-2021: findings from the 2021 Global Burden of Disease Study. Int J Surg, 2026, 112(1): 239-249.
|
| 30. |
Roth G, Mensah G, Johnson C, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study. J Am Coll Cardiol, 2020, 76(25): 2982-3021.
|
| 31. |
Li W, Xiong S, Yin S, et al. Prevalence and risk factors of mitral, tricuspid, and aortic regurgitation: a population-based study from rural northeast China. Am J Cardiol, 2023, 209: 156-162.
|
| 32. |
Si K, Hou Y, Wang J, et al. The global, regional, and national burden of non-rheumatic degenerative mitral valve disease from 1990 to 2021 and forecast for 2050. Front Cardiovasc Med, 2026, 13: 1583290.
|